Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EHMT2 | Q96KQ7 | 20/20 | 1.00 |
| ▸ | CHD1 | O14646 | 2/20 | 0.80 |
| ▸ | EHMT1 | Q9H9B1 | 3/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29382283 | 1.00 | EHMT2 (1.00) | EHMT2CHD1EHMT1 | |
| SCHEMBL25208627 | 0.99 | EHMT2 (1.00) | EHMT2CHD1EHMT1 | |
| SCHEMBL29384966 | 0.99 | EHMT2 (1.00) | EHMT2CHD1EHMT1 | |
| SCHEMBL19617550 | 0.94 | EHMT2 (0.98) | EHMT2CHD1EHMT1 | |
| SCHEMBL25230546 | 0.94 | EHMT2 (1.00) | EHMT2CHD1 | |
| SCHEMBL29385494 | 0.94 | EHMT2 (0.98) | EHMT2CHD1EHMT1 | |
| SCHEMBL25204606 | 0.94 | EHMT2 (1.00) | EHMT2EHMT1 | |
| SCHEMBL29382539 | 0.94 | EHMT2 (1.00) | EHMT2EHMT1 | |
| SCHEMBL25204668 | 0.93 | EHMT2 (1.00) | EHMT2CHD1EHMT1 | |
| SCHEMBL25235013 | 0.93 | EHMT2 (0.88) | EHMT2CHD1EHMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4192826-A1 | SMALL MOLECULES FOR THE TREATMENT OF AUTOIMMUNE DISEASES AND CANCER | Athos Therapeutics, Inc. (US) | 2023-06-14 | — | — | EP | disclosed |
| US-20230159498-A1 | SMALL MOLECULES FOR THE TREATMENT OF AUTOIMMUNE DISEASES AND CANCER | ATHOS THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
| US-11485728-B2 | Small molecules for the treatment of autoimmune diseases and cancer | ATHOS THERAPEUTICS, INC. (US) | 2022-11-01 | — | — | US | disclosed |
| US-20220073498-A1 | SMALL MOLECULES FOR THE TREATMENT OF AUTOIMMUNE DISEASES AND CANCER | ATHOS THERAPEUTICS, INC. | 2022-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159498-A1 | SMALL MOLECULES FOR THE TREATMENT OF AUTOIMMUNE DISEASES AND CANCER | SSB, HLA-DRB1, UACA | EHMT2 1523/4885CHD1 3110/4885EHMT1 1748/4885 |
| US-11485728-B2 | Small molecules for the treatment of autoimmune diseases and cancer | SSB, HLA-DRB1, UACA | EHMT2 1523/4885CHD1 3110/4885EHMT1 1748/4885 |
| US-20220073498-A1 | SMALL MOLECULES FOR THE TREATMENT OF AUTOIMMUNE DISEASES AND CANCER | SSB, HLA-DRB1, UACA | EHMT2 1523/4885CHD1 3110/4885EHMT1 1748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.